The 30 is combined between the two trials. Hopefully we get clarification of how many on each. Ultimately I think that Leronlimab will be used much earlier on (mild/moderate), but I think that the severe trial has the opportunity to be approved faster.

Unfortunately at last tally it was also lagging behind the mild trial in enrollment numbers.